{"id": "397478", "url": "https://fevir.net/resources/Evidence/397478", "meta": {"versionId": "4", "lastUpdated": "2025-09-13T18:19:04.761Z"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p><b>Title: </b>Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan</p><p><b>Variable in role of population: </b>the study group</p><p><b>Variable in role of exposure: </b>GroupAssignment: Quadpill vs. Candesartan</p><p><b>Variable in role of outcome: </b>Adverse event free and hypertension control at 12 weeks</p><p><b>Statistic: </b>odds ratio (coded as: STATO:0000182 from https://fevir.net/sevco) 0.83</p></div>", "status": "generated"}, "title": "Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan", "author": [{"name": "Brian S. Alper, MD, MSPH"}], "citeAs": "Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 397478. Revised 2025-09-13. Available at: https://fevir.net/resources/Evidence/397478. Computable resource at: https://fevir.net/resources/Evidence/397478#json.", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "publisher": "Computable Publishing LLC", "relatesTo": [{"type": "part-of", "targetReference": {"type": "Composition", "display": "Outcome Measure Report for QUARTET USA Trial", "reference": "Composition/375280"}}], "statistic": [{"quantity": {"value": 0.83}, "sampleSize": {"knownDataCount": 53, "numberOfParticipants": 62, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/number-analyzed", "valueUnsignedInt": 53}]}, "statisticType": {"coding": [{"code": "STATO:0000182", "system": "https://fevir.net/sevco", "display": "odds ratio"}]}, "numberAffected": 13, "attributeEstimate": [{"type": {"coding": [{"code": "STATO:0000196", "system": "https://fevir.net/sevco", "display": "confidence interval"}]}, "level": 0.95, "range": {"low": {"value": 0.22}, "high": {"value": 3.16}}}, {"type": {"coding": [{"code": "STATO:0000700", "system": "https://fevir.net/sevco", "display": "p-value"}]}, "quantity": {"value": 0.775}}]}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "397478", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"display": "the study group"}, "variableRole": "population"}, {"observed": {"type": "EvidenceVariable", "display": "GroupAssignment: Quadpill vs. Candesartan", "reference": "EvidenceVariable/375183"}, "variableRole": "exposure"}, {"observed": {"type": "EvidenceVariable", "display": "Adverse event free and hypertension control at 12 weeks", "reference": "EvidenceVariable/375278"}, "variableRole": "outcome"}], "name": "Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan", "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}